Gilead Sciences, Inc. $GILD Stock: Provenance Wealth Advisors LLC Raises Stake

Provenance Wealth Advisors LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 412.3% during the third quarter, Holdings Channel.com reports. The firm owned 13,418 shares of the biopharmaceutical company’s stock after acquiring an additional 10,799 shares during the period. Provenance Wealth Advisors LLC’s holdings in Gilead Sciences were worth $2,000,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Bank of Nova Scotia bought a new position in Gilead Sciences in the 2nd quarter valued at $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $55,754,000. Groupe la Francaise raised its position in shares of Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after acquiring an additional 11,712 shares during the last quarter. Baird Financial Group Inc. increased its holdings in Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Gilead Sciences in the second quarter valued at about $6,251,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.7%

NASDAQ:GILD opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $175.65. The stock has a 50-day moving average price of $151.77 and a two-hundred day moving average price of $140.25. The stock has a market cap of $207.72 billion, a price-to-earnings ratio of -53.00 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter last year, the firm posted $2.47 earnings per share. Gilead Sciences’s revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is -103.80%.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 126,881 shares of company stock valued at $19,252,455. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Morgan Stanley upped their price target on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. TD Cowen lifted their price objective on shares of Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday. HSBC boosted their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Truist Financial upped their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Needham & Company LLC set a $175.00 target price on shares of Gilead Sciences in a report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.15.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.